Vidavir 300 mg FC tablets
PDF Leaflet Revision Date: 18 November 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV-1 infection in adults aged 18 years and older.
Dosage (summary)
One tablet orally, once daily.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; effective contraception required for women of childbearing age.
Key Drug Interactions
- Rifampicin decreases dolutegravir levels
- Avoid co-administration with nephrotoxic medicines
Contraindications
- Hypersensitivity to components
- Uncontrolled renal failure
- Pregnancy and lactation
- Women not using effective contraception
- Co-administration with adefovir dipivoxil, dofetilide, pilsicainide, didanosine, metformin
Common side effects
- Lactic acidosis
- Severe hepatomegaly
- Hypersensitivity reactions
- Pancreatitis
- Renal impairment
Counselling Points
- Monitor for signs of lactic acidosis
- Avoid alcohol
- Regular liver and renal function tests recommended
- Inform about potential drug interactions
Serious warnings
- Risk of lactic acidosis and severe hepatomegaly
- Immune reconstitution inflammatory syndrome (IRIS)
- Potential for osteonecrosis
Important Disclaimer
The Vidavir 300 mg FC tablets professional information leaflet below is the property of Strides Pharma (Sa) Pty Ltd and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
